Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EGFRvIII mRNA LNP vaccine
- Development stage
- Preclinical
- Lead developer
- Providence Therapeutics
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Injection
01
Overview
The EGFRvIII mRNA LNP vaccine is an experimental cancer immunotherapy developed by Providence Therapeutics in collaboration with the University of Calgary. It is designed to treat glioblastoma (GBM) by targeting the human epidermal growth factor receptor variant III (EGFRvIII), a tumor-specific oncogenic mutation frequently expressed in GBM but absent in normal tissues. The vaccine utilizes a lipid nanoparticle (LNP) platform to deliver messenger RNA (mRNA) encoding the human EGFRvIII neoantigen. Upon administration, the vaccine stimulates the immune system to recognize and attack EGFRvIII-expressing tumor cells. Preclinical studies presented at SNO 2025 demonstrated that the vaccine re-programs the tumor microenvironment (TME), leading to an enrichment of pro-inflammatory, antigen-processing macrophages and activated cytotoxic T-cells, which resulted in significant tumor regression and complete clearance in syngeneic mouse models.
- Other names
- EGFRvIII mRNA-LNP vaccine
02
Targets
EGFRvIII (Epidermal growth factor receptor variant III)
Beyond the preview
Go deeper on EGFRvIII mRNA LNP vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EGFRvIII mRNA LNP vaccine.